PacBio Announces Fourth Quarter and Full Year 2025 Financial Results

Core Insights - PacBio reported a revenue increase of 14% year-over-year for Q4 2025, reaching $44.6 million, and a total revenue of $160.0 million for FY 2025, up from $154.0 million in FY 2024 [2][11]. Financial Performance - Q4 2025 revenue was $44.6 million, compared to $39.2 million in Q4 2024, marking a 14% increase [2]. - Consumable revenue for Q4 2025 was $21.6 million, up from $18.8 million in Q4 2024, while instrument revenue decreased to $17.3 million from $15.3 million [2]. - Gross profit for Q4 2025 was $16.6 million, compared to $10.1 million in Q4 2024, with a non-GAAP gross margin of 40% in Q4 2025 versus 31% in Q4 2024 [3][6]. - GAAP operating expenses for Q4 2025 totaled $57.8 million, significantly lower than $163.1 million in Q4 2024 [4]. - The GAAP net loss for Q4 2025 was $40.4 million, compared to a net income of $2.4 million in Q4 2024, which included a $154.4 million gain on debt restructuring [4][8]. Annual Results - For FY 2025, GAAP gross profit was $45.8 million, up from $37.3 million in FY 2024, with a non-GAAP gross margin of 40% compared to 33% in FY 2024 [6]. - GAAP operating expenses for FY 2025 were $599.6 million, compared to $511.6 million in FY 2024, while non-GAAP operating expenses decreased to $229.9 million from $289.2 million [7]. - The GAAP net loss for FY 2025 was $546.4 million, compared to a loss of $309.9 million in FY 2024 [8]. Product and Market Developments - The company placed 21 Revio systems and 42 Vega systems in Q4 2025, with a total of 61 Revio and 140 Vega systems placed for the full year [2]. - The annualized Revio pull-through per system was approximately $242,000 in Q4 2025, slightly up from $240,000 in Q4 2024 [2]. - The company highlighted record consumables revenue and growth in the clinical market, positioning itself for future growth with the upcoming launch of the SPRQ-Nx system [11]. Balance Sheet and Cash Position - As of December 31, 2025, the company had cash, cash equivalents, and investments totaling $279.5 million, down from $389.9 million a year earlier [29].